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Abstract
Background: Drug-resistant tuberculosis (TB) is a global public health problem. Adequate management requires
baseline drug-resistance prevalence data. In West Africa, due to a poor laboratory infrastructure and inadequate
capacity, such data are scarce. Therefore, the true extent of drug-resistant TB was hitherto undetermined. In 2008,
a new research network, the West African Network of Excellence for Tuberculosis, AIDS and Malaria (WANETAM),
was founded, comprising nine study sites from eight West African countries (Burkina Faso, The Gambia, Ghana,
Guinea-Bissau, Mali, Nigeria, Senegal and Togo). The goal was to establish Good Clinical Laboratory Practice (GCLP)
principles and build capacity in standardised smear microscopy and mycobacterial culture across partnering
laboratories to generate the first comprehensive West African drug-resistance data.
Methods: Following GCLP and laboratory training sessions, TB isolates were collected at sentinel referral sites
between 2009–2013 and tested for first- and second-line drug resistance.
Results: From the analysis of 974 isolates, an unexpectedly high prevalence of multi-drug-resistant (MDR) strains
was found in new (6 %) and retreatment patients (35 %) across all sentinel sites, with the highest prevalence
amongst retreatment patients in Bamako, Mali (59 %) and the two Nigerian sites in Ibadan and Lagos (39 % and
66 %). In Lagos, MDR is already spreading actively amongst 32 % of new patients. Pre-extensively drug-resistant
(pre-XDR) isolates are present in all sites, with Ghana showing the highest proportion (35 % of MDR). In Ghana
and Togo, pre-XDR isolates are circulating amongst new patients.
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Conclusions: West African drug-resistance prevalence poses a previously underestimated, yet serious public health
threat, and our estimates obtained differ significantly from previous World Health Organisation (WHO) estimates.
Therefore, our data are reshaping current concepts and are essential in informing WHO and public health strategists
to implement urgently needed surveillance and control interventions in West Africa.
Keywords: Tuberculosis, Extensively drug-resistant tuberculosis, West Africa, Drug-resistance surveillance, Capacity
building
Background
West Africa comprises 15 countries and is home to 245
million inhabitants who are highly affected by commu-
nicable diseases. A limited sub-regional health and la-
boratory infrastructure leaves the region especially
vulnerable not just to major infectious diseases, such as
tuberculosis (TB), malaria, meningitis and human im-
munodeficiency virus (HIV), but also to devastating
emerging epidemics, including the largest ever Ebola
outbreak [1]. Creating laboratory capacity and fostering
regional collaborations within West Africa will allow
countries to respond with rapid concerted action to
emerging public health threats and to conduct clinical
trials to address local health needs and inform global
health policies. To close knowledge gaps, leading scien-
tists and research institutes from the sub-region joined
forces to establish the West African Network of Excel-
lence for TB, AIDS and Malaria (WANETAM) [2].
Funded by the European and Developing Countries
Clinical Trials Partnership (EDCTP), WANETAM’s mis-
sion from 2008–2014 has been to build capacity to train
members in standardised laboratory techniques essential
to prepare the region for clinical trials and public health
relevant diagnostics and research [2]. The network is the
first of its kind and comprises nine sentinel sites from
eight West African countries: one Portuguese-speaking,
four French-speaking and three English-speaking coun-
tries (see Fig. 1).
Within the TB work package, spearheaded by the
Medical Research Council (MRC) Unit, The Gambia,
emphasis was on assessing the distribution of drug-
resistant Mycobacterium tuberculosis in West Africa, as
routine TB surveillance mechanisms and data on TB
resistance are scarce in the region [3]. Detecting multi-
drug-resistant tuberculosis (MDR-TB), defined asMycobac-
terium tuberculosis resistant to rifampicin and isoniazid,
is increasingly important, as drug resistance has
emerged as one of the biggest challenges for TB control
[4]. Furthermore, it is crucial to understand whether
prevalent MDR isolates in the region will be susceptible
to second-line drugs or have already acquired resistance
to the quinolones or injectable aminoglycosides (pre-
extensively drug-resistant [pre-XDR]) or resistance to
both classes (extensively drug-resistant [XDR]), as these
phenotypes are associated with a worse prognosis [4].
Besides the comparably low success rates of curing pa-
tients infected with MDR-TB (48 %) [4], in most West
African countries either adequate MDR therapy is not
readily available or sub-optimal treatment regimens are
in use. If we can show that drug-resistant TB is important
in WANETAM countries, this will justify implementation
of standardised (inter)national drug susceptibility testing
(DST) surveillance systems and roll-out of adequate MDR
treatment programs across West Africa. In addition, an
international TB drug resistance study prepares the region
for future multi-centre clinical TB trials of new regimens
for MDR-TB.
Methods
Training activities
The MRC Unit, The Gambia, was a named WANETAM
Node of Excellence (NoE) and became the focal point
for coordinating Good Clinical Laboratory Practice
(GCLP) and all TB-related activities. In order to prepare
the WANETAM network for a multi-centre study (and
future clinical trials), common standards between the
study sites had to be implemented. This was achieved by
conducting a series of initial workshops (see Table 1).
In parallel, laboratories of partner institutes were ini-
tially assessed in their proficiency towards performing
routine diagnostics, including smear microscopy, culture
and isolate storage. To assist the member countries in
their efforts to implement the current state-of-the-art
diagnostics, several regional workshops, during which
participants received not only theoretical knowledge but
also hands-on practice in laboratory activities, were con-
ducted (see Table 1). To guarantee comparability of diag-
nostic techniques between study sites, all assays were
performed according to disseminated Standard Operat-
ing Procedures (SOPs) and GCLP. The initial workshops
conveyed basic diagnostic methods, such as microscopy,
solid/liquid culture and storage of isolates, which pro-
vided essential knowledge needed for conducting drug
resistance surveys. To reinforce the knowledge gained
and to troubleshoot arising problems, there were 12 cus-
tomised on-site visits (consisting of 8 weeks in total) of
MRC staff to partner laboratories. Additional training
included a variety of DNA extraction protocols and
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advanced molecular methods such as phenotypic DST
testing or the Hain GenoType MTBDRplus and Gen-
Xpert MTB/RIF for genotypic DST testing. Training in a
basic genotyping method (spoligotyping) was provided
for early detection of potential outbreaks of resistant
clones. For an overview of the conducted workshops
and their detailed content, see Table 1.
Sample collection and shipment
We collected consecutive TB isolates from new and
retreatment patients (according to WHO case defini-
tions [3]) from nine West African partner institutes (see
Fig. 1) in the following eight West African countries:
Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mali,
Nigeria, Senegal and Togo. The isolates were collected
between 2009–2013 from the TB referring centres in
each capital city, and for Togo these represented coun-
trywide samples. Nigeria was the only country with two
sites, one in Lagos and the other in Ibadan. Conducting
a standardised sampling approach was challenging, as
the catchment areas of recruited patients between the
partner sites varied. For example, the Nigerian Institute
of Medical Research (NIMR) in Lagos is a countrywide
referral centre for patients with suspected drug-resistant
TB, whereas in The Gambia all of the patients were re-
cruited from the Greater Banjul Area. All isolates were
processed according to common SOPs and shipped to
MRC fully compliant with the International Air
Transport Association (IATA) Dangerous Goods Regula-
tions (https://www.iata.org/services/Microsites/DGR/en/
index.html) [5]. Resistance profiles to first- and second-
line drugs were performed at MRC Unit, The Gambia,
and isolates were archived in a biobank.
First- and second-line drug susceptibility testing
Drug susceptibility testing (DST) was performed to deter-
mine the resistance pattern of isolates to first- and second-
line anti-TB drugs. The standard protocol for DST for the
first-line drugs streptomycin (STR, 1 μg/mL), isoniazid
(INH, 0.1 μg/mL), rifampicin (RIF, 1 μg/mL) and etham-
butol (EMB, 5 μg/mL) in MGIT 960 (Becton Dickinson,
Oxford Science Park, Oxford, UK) was followed according
to the manufacturer’s instructions [6]. Phenotypic DST for
second-line drugs was performed on identified MDR iso-
lates in MGIT 960 (Becton Dickinson, Oxford Science
Park, Oxford, UK) using kanamycin (KAN, 2.5 μg/mL)
capreomycin (CAP, 2.5 μg/mL), ofloxacin (OFX, 2 μg/mL)
Fig. 1 Participating WANETAM sites. Coordinated by the Medical Research. Council Unit (MRC), The Gambia, the following partner sites were part
of the capacity building activities and drug resistance surveys: (1) Senegal, Laboratoire Bactériologie Virologie, Le Dantec, Dakar; (2) The Gambia,
National Public Health Laboratory Services, Banjul; (3) Guinea-Bissau, National Institute of Public Health (INASA), Bissau; (4) Mali, SEREFO (HIV/TB
Research and Training Center) FMOS, University of STT, Bamako; (5) Burkina Faso, Centre Muraz and the National TB Program (NTP), Ouagadougou;
(6) Ghana, Korle Bu Teaching Hospital, Accra; (7) Togo, Laboratoire National de Référence (LNR) des Mycobactéries, Lome; (8) Nigeria, Nigerian In-
stitute of Medical Research (NIMR), Lagos; (9) Nigeria, College of Medicine, University of Ibadan
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and ethionamide (ETH, 5 μg/mL) (Sigma-Aldrich, St. Louis,
Mo, USA) [7].
Quality assurance
To assure accuracy of DST results, the MRC TB Diagnos-
tics Laboratory participates in external quality assurance
from the National External Quality Assessment Service
(NEQAS), UK (http://www.ukneqas.org.uk/). A blinded
panel provided by WHO through the National Myco-
bacterium Reference Laboratory in the UK (https://
www.gov.uk/government/collections/national-mycobac-
terium-reference-laboratory-nmrl) was analysed for
quality assurance of speciation and first- and second-
line DST. In addition, a standardised susceptible H37Rv
(ATCC 27249) laboratory strain was included in each
batch. The MRC Diagnostics laboratories’ first- and
second-line DST together with other diagnostic assays
achieved ISO15189:2012 accreditation in July 2015.
Data management and statistical analysis
Sample data were entered in real time at MRC Unit, The
Gambia, into a custom-built Structured Query Language
(SQL) database with an Access front end. Data were
checked thoroughly for consistency before the database
was locked in June 2015. The extracted data were ana-
lysed using Stata/SE v12.1 (2011, Stata Statistical Soft-
ware: Release 12, StataCorp LP, College Station, TX,
USA). Categorical data were summarised using appro-
priate descriptive count and percentage statistics. To
achieve appropriate coverage, confidence intervals were
constructed using the Wilson interval. All analyses were
split by site and treatment history status (new and
retreatment).
Results
Drug resistance in West Africa
Mycobacterial collection and patient characteristics
Isolates were collected from new and retreatment pa-
tients from each of the study sites, analysed and then
archived for future research in a newly founded bio-
bank at MRC Unit, The Gambia. A total of 1568 iso-
lates were collected across the nine study sites and
sent to MRC Unit, The Gambia. Out of 1462 that
were processed, 9 % were contaminated and 25 %
were non-viable following the shipment. In total, 974
isolates (66 %) were included in the drug resistance
survey and stored at –70 °C (see Fig. 2). For an over-
view of patient demographics, including treatment
history, sex, age and HIV status, see Table 2.
Resistance to first-line drugs and MDR
In total, 39 % of all isolates were resistant to at least one
first-line drug, and MDR isolates were found at all sites
(Table 3 and Fig. 3). Consistent with previous studies,
Table 1 Capacity building and training activities within WANETAM
Year Workshop title Content Duration Location Number of
trainees
2010 Good Clinical Laboratory Practice (GCLP) Principles of GCLP 1 week MRC 18
2011 Basic Mycobacteriology Microscopy 4 weeks MRC 18
Isolation of mycobacteria
Solid and liquid culture
Storage of isolates
2013 IATA Certification Training Shipment of isolates 2 days Benin 23
2012 Molecular Epidemiology of MDR-TB in West Africa Boiled lysate/genomic DNA extraction 2 weeks MRC 18
Polymerase chain reaction (PCR)
Hain MTBDRplus
Spoligotyping
2013 Rapid Detection, Rapid Action: TB diagnosis
with GeneXpert
Background on RT-PCR testing 1 week MRC 18
GeneXpert technology and maintenance
Practical Xpert MTB/RIF
Result interpretation
2013 From Bench to Genome, a Simplified Perspective Bioinformatics course 1 day MRC 18
2014 Data Analysis and Publishing Statistics 1 week MRC 18
Critical appraisal of data
Writing skills
2010–2014 12 Visits to Partner Sites Customised training 8 weeks WANETAM sites –
MTBDRplus assay for rapid detection of multi-drug-resistant TB, Xpert MTB/RIF assay for rapid detection of TB and resistance to rifampicin
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we found that bacteria isolated from retreatment pa-
tients were more than four times more likely to be
resistant to one or more first-line drugs when compared
to mycobacteria from new patients (OR 4.4 [95 % CI
3.3–5.9]).
Amongst retreatment patients, Mali (59 %) and the
Nigerian study sites in Lagos (66 %) and Ibadan (39 %)
had the highest percentages of MDR-TB. All other study
sites had high numbers of MDR amongst retreatment
patients with The Gambia at 13 % being the lowest.
With the exception of The Gambia and Nigeria/Ibadan,
the majority of countries identified MDR isolates from
new patients, with Nigeria/Lagos (32 %) and Ghana
(13 %) reporting the largest proportions (Table 3).
Resistance to second-line drugs and XDR/pre-XDR
Amongst all MDR strains tested for second-line drug re-
sistance, no XDR was found (see Table 4). However 41
(21 %) pre-XDR strains resistant to OFX or KAN and/or
CAP were found in 199 MDR isolates. Interestingly, only
Ghana and Togo reported pre-XDR strains from new
patients, whereas pre-XDR from retreatment patients
was found in The Gambia, Ghana, Mali, Nigeria
(Ibadan/Lagos) and Togo (see Table 4, Fig. 3).
Discussion
Due to scanty data, most of West Africa remains a
‘blank’ or is classified as ‘no data’ on drug resistance
figures in WHO TB reports [3]. According to the WHO,
lack of laboratory infrastructure is responsible for this
shortcoming, and this urgently needs to be overcome
[3]. A prerequisite for conducting TB drug surveys, and
a necessity for any clinical TB trial, is the ability to suc-
cessfully perform smear microscopy in combination with
mycobacterial cultures, both of which were established
at the West African study sites within the WANETAM
network. In recently designed surveys, such as the one
in Senegal, the primary screen for rifampicin resistance
is based on the GeneXpert MTB/RIF, followed by cul-
ture and DST for rifampicin-resistant sputa and a sub-
set of the sensitive ones. Following common SOPs, the
nine WANETAM study sites collected sputa and isolated
mycobacteria using solid or liquid cultures. Ultimately
we described a comprehensive overview of drug resist-
ance in West Africa for the first time.
We found a high proportion of isolates that were re-
sistant to one or more first-line drugs (39 %) across the
West African sites. In addition almost a quarter (22 %)
of all isolates tested showed MDR phenotypes and are
Fig. 2 Flowchart of collected, shipped and processed samples included in the present study
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therefore unlikely to respond to first-line drug therapy
or even to the standardised retreatment (category II)
regimen that adds only streptomycin as the new drug to
the first-line therapy. These infections require specific
future TB control measures such as adequate diagnostics
and availability of effective therapy based on DST re-
sults. Although high rates of MDR in retreatment pa-
tients are systematically found across all WANETAM
study sites, the situation appears especially alarming in
Nigeria (Lagos 66 %, Ibadan 39 %) and Mali (59 %). In
Lagos, for instance, 32 % of all new patients with their
first ever episode of TB were already presenting with
widely circulating MDR isolates. Our findings support
previous publications from Nigeria [8–12] and Burkina
Faso [13, 14]; however, variations in the respective MDR
prevalence estimates of these publications are consider-
able, due to differences in sampling strategy, collection
time points and location, making an overall comparison
difficult. Burkina Faso, Nigeria and Niger were the only
WANETAM countries that previously reported XDR
isolates [3, 15]. Although we did not identify any XDR
isolates in our set of samples, six countries demonstrated
the emergence of pre-XDR strains. Despite having the
highest MDR prevalence, it was not the site in Lagos,
Nigeria but Ghana that yielded the highest proportion of
pre-XDR isolates in 11 % and 35 %, respectively, within
their MDR population of new and retreatment patients.
Overall, 21 % of all MDR strains were pre-XDR across
all WANETAM sites combined. As second-line treat-
ment of these strains will be impaired due to lack of sus-
ceptibility to either fluoroquinolones or injectable drugs,
these pre-XDR bacteria are on the verge of developing
the full XDR phenotype if no effective interventions are
instituted, and they constitute a major public health
threat in the region. Of further concern is that Ghana
and Togo, independently from each other, identified pre-
XDR amongst new patients. This suggests that these
strains have started spreading within the general popula-
tion of these two neighbouring West African countries,
although confirmation by molecular fingerprinting methods
of circulating isolates is needed.
To put the WANETAM results in context, we com-
pared our estimates with the latest data from the WHO
Global Tuberculosis Report 2014 (Fig. 4) [3]. To date
only three WANETAM countries conducted previous
drug-resistance surveys. While a Senegalese survey is
presently on-going and Nigeria completed a survey in
between 2009–2010 [16], data from The Gambia was
collected more than a decade ago in 1999 [17]. As no
previous data existed for several countries in 2013,
WHO reports a common MDR estimate (new patient:
1.9 % [0.1 –5.3 %], retreatment: 20 % [0.1–40 %]) for
Mali, Guinea-Bissau, Ghana and Burkina Faso.
Our results allow us to update and complement previ-
ous and/or missing data reported to WHO from these
eight WANETAM countries (see Fig. 4). While our
Table 2 Patient characteristics of study population at individual WANETAM study sites
Burkina
Faso
The
Gambia
Ghana Guinea-
Bissau
Mali Nigeria
Ibadan
Nigeria
Lagos
Senegal Togo All study
sites
n % n % n % n % n % n % n % n % n % n %
Total 27 (3) 104 (11) 127 (13) 44 (5) 208 (21) 57 (6) 120 (12) 75 (8) 212 (21) 974 (100)
Treatment history New 20 (74) 9 (9) 15 (12) 32 (73) 150 (72) 13 (23) 28 (23) 55 (73) 94 (44) 416 (43)
Retreatment 1 (4) 95 (91) 112 (88) 4 (9) 58 (28) 44 (77) 88 (73) 20 (27) 112 (53) 534 (55)
Unknown 6 (22) 0 (0) 0 (0) 8 (18) 0 (0) 0 (0) 4 (3) 0 (0) 6 (3) 24 (2)
Age 0–14 0 (0) 0 (0) 1 (1) 1 (3) 4 (2) 3 (5) 1 (1) 4 (5) 3 (1) 17 (2)
15–24 3 (14) 31 (30) 16 (13) 10 (26) 50 (24) 6 (10) 16 (14) 12 (16) 27 (13) 171 (18)
25–34 3 (14) 31 (30) 35 (29) 12 (31) 78 (38) 21 (37) 45 (39) 25 (34) 57 (27) 307 (31)
35–44 8 (38) 20 (20) 32 (26) 7 (18) 38 (18) 15 (26) 32 (28) 14 (19) 57 (27) 223 (23)
45–54 3 (14) 10 (10) 26 (21) 6 (15) 21 (10) 8 (14) 12 (10) 7 (9) 42 (20) 135 (14)
55–64 2 (10) 7 (7) 4 (3) 1 (3) 11 (5) 2 (4) 9 (8) 5 (7) 13 (6) 54 (5)
65+ 2 (10) 3 (3) 8 (7) 2 (5) 6 (3) 2 (4) 1 (1) 7 (9) 9 (4) 40 (4)
Unknown 6 – 2 - 5 - 5 – 0 – 0 – 4 – 1 – 4 – 27 (3)
Sex Female 7 (33) 31 (30) 29 (24) 18 (44) 51 (25) 23 (40) 54 (46) 17 (23) 76 (36) 306 (31)
Male 14 (67) 73 (70) 93 (76) 23 (56) 157 (75) 34 (60) 63 (54) 58 (77) 136 (64) 650 (67)
Unknown 6 – 0 - 5 - 3 – 0 – 0 – 3 – 0 – 1 – 18 (2)
HIV Negative 0 (0) 56 (54) 25 (20) 0 (0) 172 (83) 42 (74) 46 (38) 15 (20) 115 (54) 471 (48)
Positive 0 (0) 5 (5) 3 (2) 12 (27) 29 (14) 4 (7) 27 (23) 12 (16) 36 (17) 128 (14)
Unknown 27 (100) 43 (41) 99 (78) 32 (73) 7 (3) 11 (19) 47 (39) 48 (64) 61 (29) 375 (38)
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estimates are in concordance for Togo and Senegal, we
found significantly higher MDR prevalence in retreat-
ment patients in the Nigerian and Malian sites when
compared with the WHO estimated data [3]. This is
not surprising, especially in Nigeria, where a 2012
nationwide TB prevalence survey found WHO esti-
mates were 50 % of the true TB burden [16]. In contrast
to the WHO estimates, none of the confidence intervals
from our nine study sites included zero (in retreatment
patients), providing strong evidence that MDR isolates
Table 3 First-line drug resistance by study site and treatment history
Study site Treatment
history
First-line drug resistance Total DST profiles of resistant isolates
Pan susceptible Any resistance RMP mono INH mono SM mono EMB mono PDR MDR
N % n % N % n % n % n % N % n %
Burkina Faso All 18 (67) 9 (33) 27 0 (0) 2 (7) 1 (4) 0 (0) 4 (15) 2 (7)
New 13 (65) 7 (35) 20 0 (0) 2 (10) 1 (5) 0 (0) 3 (15) 1 (5)
Retreatment 0 (0) 1 (100) 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
Unknown 5 (83) 1 (17) 6 0 (0) 0 (0) 0 (0) 0 (0) 1 (17) 0 (0)
The Gambia All 80 (77) 24 (23) 104 1 (1) 4 (4) 6 (6) 0 (0) 1 (1) 12 (11)
New 7 (78) 2 (22) 9 0 (0) 1 (11) 1 (11) 0 (0) 0 (0) 0 (0)
Retreatment 73 (77) 22 (23) 95 1 (1) 3 (3) 5 (5) 0 (0) 1 (1) 12 (13)
Ghana All 64 (50) 63 (50) 127 1 (0) 7 (5) 13 (10) 0 (0) 9 (7) 33 (26)
New 11 (73) 4 (27) 15 0 (0) 1 (7) 1 (7) 0 (0) 0 (0) 2 (13)
Retreatment 53 (47) 59 (53) 112 1 (1) 6 (5) 12 (11) 0 (0) 9 (8) 31 (28)
Guinea-Bissau All 34 (77) 10 (23) 44 2 (4) 1 (2) 1 (2) 1 (2) 2 (5) 3 (7)
New 24 (75) 8 (25) 32 2 (6) 1 (3) 1 (3) 1 (3) 2 (6) 1 (3)
Retreatment 2 (50) 2 (50) 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (50)
Unknown 8 (100) 0 (0) 8 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mali All 143 (69) 65 (31) 208 1 (0) 7 (3) 7 (3) 0 (0) 11 (5) 39 (19)
New 127 (85) 23 (15) 150 1 (1) 7 (5) 6 (4) 0 (0) 4 (3) 5 (3)
Retreatment 16 (28) 42 (72) 58 0 (0) 0 (0) 1 (2) 0 (0) 7 (12) 34 (59)
Nigeria/Ibadan All 31 (54) 26 (46) 57 1 (2) 1 (2) 4 (7) 0 (0) 3 (5) 17 (30)
New 11 (85) 2 (15) 13 0 (0) 1 (8) 1 (8) 0 (0) 0 (0) 0 (0)
Retreatment 20 (45) 24 (55) 44 1 (2) 0 (0) 3 (7) 0 (0) 3 (7) 17 (39)
Nigeria/Lagos All 27 (22) 93 (78) 120 0 (0) 6 (5) 11 (9) 0 (0) 5 (4) 71 (59)
New 11 (40) 17 (61) 28 0 (0) 1 (4) 5 (18) 0 (0) 2 (7) 9 (32)
Retreatment 16 (18) 72 (82) 88 0 (0) 5 (6) 6 (7) 0 (0) 3 (3) 58 (66)
Unknown 0 (0) 4 (100) 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (100)
Senegal All 60 (80) 15 (20) 75 0 (0) 3 (4) 1 (1) 0 (0) 3 (4) 8 (11)
New 49 (90) 6 (11) 55 0 (0) 1 (2) 1 (2) 0 (0) 1 (2) 3 (5)
Retreatment 11 (55) 9 (45) 20 0 (0) 2 (10) 0 (0) 0 (0) 2 (10) 5 (25)
Togo All 142 (67) 70 (33) 212 4 (2) 14 (7) 16 (7) 1 (0) 5 (2) 30 (14)
New 79 (84) 15 (16) 94 1 (1) 1 (1) 7 (7) 0 (0) 1 (1) 5 (5)
Retreatment 62 (55) 50 (45) 112 3 (3) 13 (12) 8 (7) 1 (1) 3 (3) 22 (20)
Unknown 1 (17) 5 (83) 6 0 (0) 0 (0) 1 (17) 0 (0) 1 (17) 3 (50)
All study sites All 599 (61) 375 (39) 974 10 (1) 45 (5) 60 (6) 2 (0) 43 (4) 215 (22)
New 332 (80) 84 (20) 416 4 (1) 16 (4) 24 (6) 1 (0) 13 (3) 26 (6)
Retreatment 253 (47) 281 (53) 534 6 (1) 29 (5) 35 (7) 1 (0) 28 (5) 182 (34)
Unknown 14 (58) 10 (42) 24 0 (0) 0 (0) 1 (4) 0 (0) 2 (8) 7 (29)
The overall proportion of resistance to any drug is displayed as well as a detailed description of resistant isolates and their resistant patterns, stratified by
mono-resistance to rifampicin (RMP), isoniazid (INH), streptomycin (SM), ethambutol (EMB), poly-drug-resistance (PDR, resistance to a combination of any two
first-line drugs except for MDR) and multi-drug-resistance (MDR, resistance to at least both RMP and INH)
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are truly prevalent at all sites (Fig. 4). WANETAM
data tend to be higher than WHO prevalences,
highlighting the possibility that drug resistance in
West Africa is currently underestimated (see Fig. 4).
For instance, amongst new and retreatment patients,
respectively, five out of nine and seven out of nine
WANETAM sites were above the global TB prevalence
average, and seven out of nine and eight out of nine
WANETAM sites were above the estimated African
MDR prevalence average.
Our study has limitations. First of all, sample collec-
tion in Burkina Faso and Guinea-Bissau was limited, and
therefore the sample sizes were relatively small. We
accounted for that by displaying 95 % CI for all study
sites wherever appropriate. Secondly, selection bias
based on the ‘catchment’ populations of the participating
sites is likely to contribute to the high resistance rates,
especially at NIMR in Lagos, which included a referral
population who had been identified as resistant else-
where. Also, despite thorough training, we cannot
Fig. 3 Geographical distribution and prevalence of drug-resistant M. tuberculosis complex isolates in WANETAM study sites. The proportions of
resistant strains within the total bacterial population per country are mapped (for Nigeria the average of the two study sites, Lagos and Ibadan, is
displayed). The maps are stratified by new (left column) and retreatment patients (right column). The upper panel shows geographical distribution
of the proportion of isolates with any first-line drug resistance. The centre panel shows the proportion of MDR amongst the total bacterial
population. The lower panel shows the proportional geographical distribution of pre-XDR within the total population of MDR isolates. The
sample sizes for each country are as follows (country name [n = new patients/n = retreatment patients]): Burkina Faso [20/1], The Gambia
[9/95], Ghana [15/112], Guinea-Bissau [32/4], Mali [150/58], Nigeria [41/132] (Lagos and Ibadan combined), Senegal [55/20], Togo [94/112]
(for further details see Tables 3 and 4)
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exclude the potential misclassification of treatment his-
tory (new versus retreatment) or infer the missing treat-
ment history data. As no HIV status data were available
for the majority of the patients, we were not able to in-
vestigate the role of HIV co-infection on MDR rates in
our study. Finally, we did not include amikacin in the
second-line DST, as it was not sustainably available in
West Africa at the time of the initiation of the WANE-
TAM network in 2009.
The presented MDR data, together with the docu-
mented emerging spread of pre-XDR in Ghana and
Togo, indicate that the drug-resistance problem in West
Africa may be greater than currently assumed, highlight-
ing the urgent need for countrywide drug resistance sur-
veys according to WHO guidelines. While awaiting such
robust and unbiased results, our data should already
prompt the implementation of continuous surveillance
of all retreatment patients in participating countries.
Table 4 Second-line drug resistance by study site and treatment history
Study site Treatment
history
Second-line drug resistance amongst MDR Total MDR
with second-line
DST done
Pre-XDR drug resistance profiles of MDR isolates
Susceptible Pre-XDR Fluoroquinolones Injectables
OFX KAN CAP KAN/CAP
N % n % n % n % n % n %
Burkina Faso All 1 (100) 0 (0) 1 0 (0) 0 (0) 0 (0) 0 (0)
New – – – – 0 – – – – – – – –
Retreatment 1 (100) 0 (0) 1 0 (0) 0 (0) 0 (0) 0 (0)
The Gambia All 9 (75) 3 (25) 12 0 (0) 0 (0) 2 (17) 1 (8)
New 0 (0) 0 (0) 0 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 9 (75) 3 (25) 12 0 (0) 0 (0) 2 (17) 1 (8)
Ghana All 20 (61) 13 (39) 33 3 (9) 2 (6) 7 (21) 1 (3)
New 0 (0) 2 (100) 2 0 (0) 2 (100) 0 (0) 0 (0)
Retreatment 20 (65) 11 (35) 31 3 (10) 0 (0) 7 (23) 1 (3)
Guinea-Bissau All 1 (100) 0 (0) 1 0 (0) 0 (0) 0 (0) 0 (0)
New 1 (100) 0 (0) 1 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment – – – – 0 – – – – – – – –
Mali All 30 (79) 8 (21) 38 1 (3) 1 (3) 5 (13) 1 (3)
New 5 (100) 0 (0) 5 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 25 (76) 8 (24) 33 1 (3) 1 (3) 5 (16) 1 (3)
Nigeria/Ibadan All 13 (76) 4 (23) 17 2 (12) 0 (0) 2 (12) 0 (0)
New 0 (0) 0 (0) 0 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 13 (76) 4 (23) 17 2 (12) 0 (0) 2 (12) 0 (0)
Nigeria/Lagos All 59 (91) 6 (9) 65 6 (9) 0 (0) 0 (0) 0 (0)
New 8 (100) 0 (0) 8 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 51 (89) 6 (11) 57 6 (10) 0 (0) 0 (0) 0 (0)
Senegal All 5 (100) 0 (0) 5 0 (0) 0 (0) 0 (0) 0 (0)
New 2 (100) 0 (0) 2 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 3 (100) 0 (0) 3 0 (0) 0 (0) 0 (0) 0 (0)
Togo All 20 (74) 7 (26) 27 1 (4) 1 (4) 3 (11) 2 (7)
New 2 (40) 3 (60) 5 1 (20) 0 (0) 1 (20) 1 (20)
Retreatment 18 (82) 4 (18) 22 0 (0) 1 (4) 2 (9) 1 (4)
All study sites All 158 (79) 41 (21) 199 12 (6) 4 (2) 19 (9) 6 (3)
New 18 (78) 5 (22) 23 1 (4) 2 (9) 1 (4) 1 (4)
Retreatment 140 (80) 36 (20) 176 11 (6) 2 (1) 18 (10) 5 (3)
No extensively drug-resistant isolates (XDR) were found in the survey. The proportion of pre-XDR within the population of MDR isolates is displayed as well as a
detailed description of pre-XDR isolates and their resistance patterns, stratified by mono-resistance to ofloxacin (OFX), kanamycin (KAN) and capreomycin (CAP)
and the combination of the latter two (KAN/CAP)
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Such a system is ideally based on molecular screens,
such as with the GeneXpert MTB/RIF, followed by add-
itional molecular and phenotypic testing at the National
Reference Laboratories. Moreover, the increasing detec-
tion of patients with MDR-TB stresses the need for the
wider availability of effective treatment. Such efforts are
Fig. 4 Comparison between WANETAM (blue) and WHO Global TB report, 2014 (red) MDR prevalence estimates. The country-specific WHO esti-
mates were retrieved from the recent Global TB report, 2014, at http://www.who.int/tb/country/data/profiles/en/ (accessed 11.08.2015). The mean
(triangle) percentage of MDR per all TB isolates is given for each country/study site and Africa, together with the respective 95 % CI. The upper
panel shows results for new patients, the lower panel retreatment patients. The shaded areas display the global average (dotted line), including the
range from the lower to upper limit of the 95 % CI. Note that in case of a potential strong selection bias, a limitation of the present study, the
confidence intervals around the WANETAM mean might still reflect an overestimate of the true prevalence
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already on-going, such as the roll-out of the 9-month
short-course MDR regimen [18] in West and Central
African countries with support from the International
Union Against Tuberculosis and Lung Disease (IUTLD),
beyond Niger, Benin and Cameroon [19, 20], which were
early adopters of this regimen and report high rates of
treatment success. As demonstrated, the WANETAM
network has established essential laboratory capacity to
conduct future clinical TB trials. A major challenge,
however, for any successful network is its capability to
function sustainably and independently. Encouragingly,
WANETAM’s capacity building efforts have already had
several positive consequences for member states beyond
the initially defined network activities. For instance, the
National TB Program of The Gambia recently conducted
the first Gambian TB prevalence study, The Gambian
Survey of Tuberculosis Prevalence (GAMSTEP). Simi-
larly, the Chest Clinic Laboratory at the Korle-Bu Teach-
ing Hospital in Ghana, which did not perform culture in
the past, was accredited as the country’s National TB
Reference Laboratory in the course of the WANETAM
project. SEREFO in Bamako was selected as the diagnos-
tic laboratory during the Malian response to the Ebola
epidemic in 2014. During the same outbreak, IATA cer-
tified shippers in multiple countries, trained by WANE-
TAM, were often the only staff available to send clinical
samples of Ebola patients to respective reference
laboratories. Most encouragingly, Senegal, Mali and
Benin have hosted their own regional workshops in
which both WANETAM member and non-member
states, such as Chad, Rwanda or Democratic Republic of
Congo (amongst others), were trained in classical micro-
biological and molecular methods.
Conclusion
WANETAM accomplished the first steps in producing
regional TB research of public health relevance in West
Africa. As the established TB network is entirely based
on South-South collaborations, partners face both simi-
lar and unique challenges, and can reach out across the
region for further training exchanges and research col-
laborations. WANETAM is a crucial stepping stone in
moving West Africa forward towards independent and
internationally competitive TB research, for both the in-
dividual institutes and for multi-centred TB trials across
the whole sub-region.
One of the most important achievements of WANE-
TAM so far is the finding that drug-resistant TB could
become a serious public health problem in West Africa
if required control measures are not taken. This is not
only because of high drug-resistant TB rates amongst
retreatment patients but especially amongst new pa-
tients, showing that on-going transmission is currently
insufficiently controlled. As the problem of emerging
drug resistance is multi-facetted and sub-regional,
control strategies need to improve on various levels and
between countries. Implementing required quality stan-
dards (SOPs and GCLP) and laboratory infrastructure,
as done by WANETAM, can therefore only be a first
step in the successful control of drug-resistant TB in
West Africa. We hope that our data could serve as a
foundation for common West African guidelines and
policies, jointly developed by the individual National TB
Programs (NTPs) under the guidance of the West
African Health Organisation (WAHO). Those guidelines
are needed to ultimately tackle the challenges the sub-
region is facing. Ideally, scientific networks, such as
WANETAM, should consequently be maintained as
powerful platforms that would have the capacity to bring
the various stakeholders together and facilitate such a
process. Therefore, we encourage international donors,
such as EDCTP or WHO, to provide further future
funds to allow the creation of new and continuation of
already existing scientific networks in Africa and the de-
veloping world.
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